NCT01327729 - Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2013

Conditions

Self EfficacyHepatitis C

Interventions

DRUG

pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg

YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group

Trial Locations (1)

RECRUITING

Kasr Alaini school of medicne, Cairo